Stellaria yunnanensis Franch and its active constituent 20-hydroxyecdysone ameliorate renal failure

Abstract

Chronic renal failure (CRF) is a progressive disease characterized by a sustained loss of kidney function, for which current therapies remain insufficient. Growing evidence closely links the CRF pathogenesis to renal aging; therefore, targeting aging processes might have therapeutic promise. Herein, we implemented a novel strategy to identify potential anti-CRF agents from anti-aging Chinese herbal medicines. Phenotypic screening indicated that the 75% ethanol extract of Stellaria yunnanensis Franch ( JM11002) exhibited marked anti-aging activity, by prolonging the lifespan of Caenorhabditis elegans and decreasing the proportion of SA-β-gal-positive senescent MRC-5 cells. Importantly, JM11002 also ameliorated renal dysfunction, inflammation, and fibrosis in both unilateral ischemia-reperfusion injury (UIRI) and unilateral ureteral obstruction (UUO) mouse models. Phytochemical investigation identified 20-hydroxyecdysone ( JM11201), a major active component of JM11002, which recapitulated the renoprotective effects in both the UUO model and unilateral ischemia-reperfusion injury with contralateral nephrectomy (UIRIx) model. Mechanistically, 20-hydroxyecdysone suppressed the TGF-β1/Smad3 signaling pathway and decreased the expression of fibrosis-related proteins in UUO kidneys. In summary, through an aging-intervention strategy, we discovered the renoprotective effect of Stellaria yunnanensis Franch extract and its active component, 20-hydroxyecdysone, two promising candidates for the development of novel CRF therapies.

Keywords

Stellaria yunnanensis Franch / 20-hydroxyecdysone / chronic renal failure / anti-aging

References

[1] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024, 105: S117-S314.

[2] Chen TK, Knicely DH, Grams ME: Chronic Kidney Disease Diagnosis and Management: A Review. Jama 2019, 322: 1294-1304.

[3] Rockey DC, Bell PD, Hill JA: Fibrosis - A Common Pathway to Organ Injury and Failure. New England Journal of Medicine 2015, 372: 1138-1149.

[4] GBD 2023 Chronic Kidney Disease Collaborators: Global, Regional, and National Burden of Chronic Kidney Disease in Adults, 1990-2023, and its Attributable Risk Factors: A Systematic Analysis for the Global Burden of Disease Study 2023. Lancet 2025, 406: 2461-2482.

[5] Bolona CEA, Winkelmayer WC: In Advanced CKD, ACEis or ARBs Reduce Kidney Failure vs. Placebo or Non-RAAS Inhibitors at 34 Mo. Annals of Internal Medicine 2024, 177: JC113.

[6] van der Aart-van der Beek AB, De Boer RA, Heerspink HJL: Kidney and Heart Failure Outcomes Associated with SGLT2 Inhibitor Use. Nature Reviews Nephrology 2022, 18: 294-306.

[7] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR: Targeting the Progression of Chronic Kidney Disease. Nature Reviews Nephrology 2020, 16: 269-288.

[8] Jun HR, Kim H, Lee SH, Cho JH, Lee H, Yim HW, et al.: Onset of Hyperkalemia Following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker. Cardiovascular Therapeutics 2021, 2021: 5935149.

[9] Huang R, Fu P, Ma L: Kidney Fibrosis: From Mechanisms to Therapeutic Medicines. Signal Transduction and Targeted Therapy 2023, 8: 129.

[10] Kishi S, Kadoya H, Kashihara N: Treatment of Chronic Kidney Disease in Older Populations. Nature Reviews Nephrology 2024, 20: 586-602.

[11] Papacocea RI, Timofte D, Tanasescu MD, Balcangiu-Stroescu AE, Balan DG, Tulin A, et al.: Kidney Aging Process and the Management of the Elderly Patient with Renal Impairment (Review). Experimental and Therapeutic Medicine 2021, 21: 266.

[12] Merchant AA, Ling E: An Approach to Treating Older Adults with Chronic Kidney Disease. Canadian Medical Association Journal 2023, 195: E612-E618.

[13] Yang HC, Fogo AB: Fibrosis and Renal Aging. Kidney International Supplements (2011) 2014, 4: 75-78.

[14] Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al.: Cellular Senescence: Defining a Path Forward. Cell 2019, 179: 813-827.

[15] Hommos MS, Glassock RJ, Rule AD: Structural and Functional Changes in Human Kidneys with Healthy Aging. Journal of the American Society of Nephrology 2017, 28: 2838-2844.

[16] Yamamoto T, Isaka Y: Pathological Mechanisms of Kidney Disease in Ageing. Nature Reviews Nephrology 2024, 20: 603-615.

[17] Zhang Q, Bai B, Ran L, Zhang W: Identification of Potential Anti Aging Drugs and Targets in Chronic Kidney Disease. Scientific Reports 2025, 15: 15545.

[18] Lin Y, Zhen Y, Wei J, Liu B, Yu Z, Hu G: Effects of Rhein Lysinate on H₂O₂-Induced Cellular Senescence of Human Umbilical Vascular Endothelial Cells . Acta Pharmacologica Sinica 2011, 32: 1246-1252.

[19] Ijima S, Saito Y, Nagaoka K, Yamamoto S, Sato T, Miura N, et al.: Fisetin Reduces the Senescent Tubular Epithelial Cell Burden and also Inhibits Proliferative Fibroblasts in Murine Lupus Nephritis. Frontiers in Immunology 2022, 13: 960601.

[20] Li X, Qiu W, Li J, Chen X, Hu Y, Gao Y, et al.: First-Generation Species-Selective Chemical Probes for Fluorescence Imaging of Human Senescence-Associated β-Galactosidase. Chemical Science 2020, 11: 7292-7301.

[21] Song Y, Li X, Shi D, Sun T, Liu W, Li X, et al.: A Senolysis-Based Theragnostic Prodrug Strategy Towards Chronic Renal Failure. Chemical Science 2022, 13: 11738-11745.

[22] Chen DQ, Feng YL, Cao G, Zhao YY: Natural Products as a Source for Antifibrosis Therapy. Trends in Pharmacological Sciences 2018, 39: 937-952.

[23] El-Ashram S, El-Samad LM, Basha AA, El Wakil A: Naturally-Derived Targeted Therapy for Wound Healing: Beyond Classical Strategies. Pharmacological Research 2021, 170: 105749.

[24] Deng R, Gu C, Wang J, Li X, Xin X, Yang Y, et al.: Stellarin I: A Bioactive Cyclic Nonapeptide with Potent Anti-renal Fibrosis Activity from the Root of Stellaria yunnanensis Franch. Chemistry & Biodiversity 2025, 22: e02177.

[25] Liu W, Guan Y, Qiao S, Wang J, Bao K, Mao Z, et al.: Antiaging Effects of Vicatia thibetica de Boiss Root Extract on Caenorhabditis elegans and Doxorubicin-Induced Premature Aging in Adult Mice . Oxidative Medicine and Cellular Longevity 2021, 2021: 9942090.

[26] Mallek A, Semiane N, Mokeddem K, Bellahreche Z, Sihali BO, Dahmani Y: Beneficial Effect of 20-Hydroxyecdysone on Kidney Damage in Streptozotocin-Induced Diabetic Gerbil. International Journal of Morphology 2025, 43: 2138-2146.

[27] Hung TJ, Chen WM, Liu SF, Liao TN, Lee TC, Chuang LY, et al.: 20-Hydroxyecdysone Attenuates TGF-β1-Induced Renal Cellular Fibrosis in Proximal Tubule Cells. Journal of Diabetes and Its Complications 2012, 26: 463-469.

[28] Han B, Sivaramakrishnan P, Lin CJ, Neve IAA, He J, Tay LWR, et al.: Microbial Genetic Composition Tunes Host Longevity. Cell 2017, 169: 1249-1262.E13.

[29] Xiao X, Zhang X, Zhang C, Li J, Zhao Y, Zhu Y, et al.: Toxicity and Multigenerational Effects of Bisphenol S Exposure to Caenorhabditis elegans on Developmental, Biochemical, Reproductive and Oxidative Stress . Toxicology Research 2019, 8: 630-640.

[30] Wilson MA, Shukitt-Hale B, Kalt W, Ingram DK, Joseph JA, Wolkow CA: Blueberry Polyphenols Increase Lifespan and Thermotolerance in Caenorhabditis elegans . Aging Cell 2006, 5: 59-68.

[31] Bao K, Liu W, Song Z, Feng J, Mao Z, Bao L, et al.: Crotamiton Derivative JM03 Extends Lifespan and Improves Oxidative and Hypertonic Stress Resistance in Caenorhabditis elegans via Inhibiting OSM-9 . Elife 2022, 11: e72410.

[32] Yuan Q, Ren Q, Li L, Tan H, Lu M, Tian Y, et al.: A Klotho-Derived Peptide Protects Against Kidney Fibrosis by Targeting TGF-β Signaling. Nature Communications 2022, 13: 438.

[33] Zhang B, Chen ZY, Jiang Z, Huang S, Liu XH, Wang L: Nephroprotective Effects of Cardamonin on Renal Ischemia Reperfusion Injury/UUO-Induced Renal Fibrosis. Journal of Agricultural and Food Chemistry 2023, 71: 13284-13303.

[34] Zhou JB, Zheng YL, Zeng YX, Wang JW, Pei Z, Pang JY: Marine Derived Xyloketal Derivatives Exhibit Anti-Stress and Anti-Ageing Effects Through HSF Pathway in Caenorhabditis elegans . European Journal of Medicinal Chemistry 2018, 148: 63-72.

[35] Odinokov VN, Galyautdinov IV, Nedopekin DV, Khalilov LM, Shashkov AS, Kachala VV, et al.: Phytoecdysteroids from the Juice of Serratula coronata L. (Asteraceae) . Insect Biochemistry and Molecular Biology 2002, 32: 161-165.

[36] Trân K, Van Den Hauwe R, Sainsily X, Couvineau P, Côté J, Simard L, et al.: Constraining the Side Chain of C-Terminal Amino Acids in Apelin-13 Greatly Increases Affinity, Modulates Signaling, and Improves the Pharmacokinetic Profile. Journal of Medicinal Chemistry 2021, 64: 5345-5364.

[37] Shang C, Zhao C, Nie P, Liu J, Du Y: Effective Total Synthesis of Schaftoside. Tetrahedron 2021, 91: 132216.

[38] Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, et al.: Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD. Journal of the American Society of Nephrology 2024, 35: 202-215.